Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer

Systemic treatment of hormone receptor-positive (HR+) breast cancer is undergoing a renaissance, with a number of targeted therapies including CDK4/6, mTOR, and PI3K inhibitors now approved for use in combination with endocrine therapies. The increased use of targeted therapies has changed the natur...

Descripción completa

Detalles Bibliográficos
Autores principales: Freelander, Allegra, Brown, Lauren J., Parker, Andrew, Segara, Davendra, Portman, Neil, Lau, Brandon, Lim, Elgene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922594/
https://www.ncbi.nlm.nih.gov/pubmed/33671468
http://dx.doi.org/10.3390/genes12020285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922594/
https://www.ncbi.nlm.nih.gov/pubmed/33671468
http://dx.doi.org/10.3390/genes12020285

Ejemplares similares